(AOF) – Inventiva joins forces with Echosens, the designer of Fibroscan, a diagnostic solution for liver health, to “raise awareness of NASH (non-alcoholic steatohepatitis) and facilitate access to screening for patients who are at risk of developing this disease. Biotech recalls that Nash is a chronic and progressive metabolic disease of the liver which, if not diagnosed or treated, can progress to cirrhosis or liver cancer and make a liver transplant necessary.
This awareness and screening program will take place in ten at-risk communities in the United States and Europe and will be supported by experts in hepatology as well as patient associations and local organizations.
NASH is a disease whose prevalence is both high and growing: it affects between 1.5% and 6.45% of the world’s population, a proportion which is expected to increase by 63% by 2030, according to studies. published in scientific journals. There is therefore an urgent need to diagnose patients in whom the disease is at high risk of progression. It is with the aim of facilitating access to screening by FibroScan, Echosens’ technology, in local communities that Inventiva and Echosens have decided to join forces.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.